How to mechanistically explain the CONDOR study data

Medical Hypotheses

Volumn 84, Issue 1, 2015, Pages 14-19

  Spies, C M ^a   Stemmler, E ^b   Buttgereit, F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; BILE SALT; CELECOXIB; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; INDOMETACIN; MEMBRANE PHOSPHOLIPID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; CYCLOOXYGENASE 2 INHIBITOR; PROTON PUMP INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; CELL MEMBRANE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTHESIS; INTESTINE MUCOSA PERMEABILITY; LIPOPHILICITY; MEMBRANE FLUIDITY; MICELLE; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; OSTEOARTHRITIS; OXIDATIVE PHOSPHORYLATION; PHYSICAL CHEMISTRY; PROSTAGLANDIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CHAIN; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; INTESTINE MUCOSA;

ARTHRITIS, RHEUMATOID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; HUMANS; INTESTINAL MUCOSA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OMEPRAZOLE; OSTEOARTHRITIS; OXIDATIVE PHOSPHORYLATION; PROTON PUMP INHIBITORS; PYRAZOLES; SULFONAMIDES;

EID: 84918492823     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.11.007     Document Type: Article

References (60)

1. Rostom A., Muir K., Dube C., et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007, 5:818-828.
2. Singh G., Fort J.G., Goldstein J.L., et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006, 119:255-266.
3. Niculescu L., Li C., Huang J., Mallen S. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin 2009, 25:729-740.
4. Emery P., Zeidler H., Kvien T.K., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999, 354:2106-2111.
5. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000, 284:1247-1255.
6. Hrachovec J.B., Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 2001, 286:2398. [author reply 2399-2400].
7. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110.
8. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005, 118:1271-1278.
9. Chan F.K., Cryer B., Goldstein J.L., et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 2010, 37:167-174.
10. Chan F.K., Lanas A., Scheiman J., Berger M.F., Nguyen H., Goldstein J.L. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010, 376:173-179.
11. Goldstein J.L., Eisen G.M., Lewis B., et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007, 25:1211-1222.
12. Goldstein J.L., Eisen G.M., Lewis B., et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005, 3:133-141.
13. Schoen R.T., Vender R.J. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989, 86:449-458.
14. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232-235.
15. Whittle B.J. Mechanisms underlying gastric mucosal damage induced by indomethacin and bile-salts, and the actions of prostaglandins. Br J Pharmacol 1977, 60:455-460.
16. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888-1899.
17. Penning T.D., Talley J.J., Bertenshaw S.R., et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997, 40:1347-1365.
18. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008, 11:81s-110s.
19. Bjarnason I., Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009, 44(Suppl. 19):23-29.
20. Mahmud T., Scott D.L., Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996, 55:211-213.
21. Tibble J.A., Sigthorsson G., Foster R., Bjarnason I. Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol 2000, 35:802-807.
22. Smecuol E., Bai J.C., Sugai E., et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 2001, 49:650-655.
23. Whitehouse M.W., Haslam J.M. Ability of some antirheumatic drugs to uncouple oxidative phosphorylation. Nature 1962, 196:1323-1324.
24. Mingatto F.E., Santos A.C., Uyemura S.A., Jordani M.C., Curti C. In vitro interaction of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: respiration and ATP synthesis. Arch Biochem Biophys 1996, 334:303-308.
25. Mahmud T., Rafi S.S., Scott D.L., Wrigglesworth J.M., Bjarnason I. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum 1996, 39:1998-2003.
26. Masubuchi Y., Yamada S., Horie T. Diphenylamine as an important structure of nonsteroidal anti-inflammatory drugs to uncouple mitochondrial oxidative phosphorylation. Biochem Pharmacol 1999, 58:861-865.
27. Somasundaram S., Sigthorsson G., Simpson R.J., et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther 2000, 14:639-650.
28. Somasundaram S., Rafi S., Hayllar J., et al. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997, 41:344-353.
29. Krauss S., Buttgereit F., Brand M.D. Effects of the mitogen concanavalin A on pathways of thymocyte energy metabolism. Biochim Biophys Acta 1999, 1412:129-138.
30. Buttgereit F., Brand M.D., Muller M. ConA induced changes in energy metabolism of rat thymocytes. Biosci Rep 1992, 12:109-114.
31. Buttgereit F., Grant A., Muller M., Brand M.D. The effects of methylprednisolone on oxidative phosphorylation in Concanavalin-A-stimulated thymocytes. Top-down elasticity analysis and control analysis. Eur J Biochem/FEBS 1994, 223:513-519.
32. Chan K., Truong D., Shangari N., O'Brien P.J. Drug-induced mitochondrial toxicity. Expert Opin Drug Metab Toxicol 2005, 1:655-669.
33. Terada H. Uncouplers of oxidative phosphorylation. Environ Health Perspect 1990, 87:213-218.
34. Krause M.M., Brand M.D., Krauss S., et al. Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis Rheum 2003, 48:1438-1444.
35. Argese E., Bettiol C., Giurin G., Miana P. Quantitative structure-activity relationships for the toxicity of chlorophenols to mammalian submitochondrial particles. Chemosphere 1999, 38:2281-2292.
36. Lipworth B.J. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000, 356:87-89.
37. Schmid D., Burmester G.R., Tripmacher R., Kuhnke A., Buttgereit F. Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. Biosci Rep 2000, 20:289-302.
38. Naumann L., Feist E., Straub R.H., Burmester G.R., Buttgereit F. Potencies of topical glucocorticoids to mediate genomic and nongenomic effects on human peripheral blood mononuclear cells. Biochem Pharmacol 2006, 71:530-539.
39. Buttgereit F., Brand M.D., Burmester G.R. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 1999, 58:363-368.
40. Petrescu I., Tarba C. Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Biochim Biophys Acta 1997, 1318:385-394.
41. Sousa C., Nunes C., Lucio M., et al. Effect of nonsteroidal anti-inflammatory drugs on the cellular membrane fluidity. J Pharm Sci 2008, 97:3195-3206.
42. Lucio M., Ferreira H., Lima J.L., Reis S. Use of liposomes to evaluate the role of membrane interactions on antioxidant activity. Anal Chim Acta 2007, 597:163-170.
43. Ferreira H., Lucio M., Lima J.L., Cordeiro-da-Silva A., Tavares J., Reis S. Effect of anti-inflammatory drugs on splenocyte membrane fluidity. Anal Biochem 2005, 339:144-149.
44. Sade A., Banerjee S., Severcan F. Concentration-dependent differing actions of the nonsteroidal anti-inflammatory drug, celecoxib, in distearoyl phosphatidylcholine multilamellar vesicles. J Liposome Res 2010, 20:168-177.
45. Gamerdinger M., Clement A.B., Behl C. Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production. Mol Pharmacol 2007, 72:141-151.
46. Sade A., Tuncay S., Cimen I., Severcan F., Banerjee S. Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression. Biosci Rep 2012, 32:35-44.
47. Ferreira H., Lucio M., Lima J.L., Matos C., Reis S. Effects of diclofenac on EPC liposome membrane properties. Anal Bioanal Chem 2005, 382:1256-1264.
48. Manrique-Moreno M., Garidel P., Suwalsky M., Howe J., Brandenburg K. The membrane-activity of ibuprofen, diclofenac, and naproxen: a physico-chemical study with lecithin phospholipids. Biochim Biophys Acta 2009, 1788:1296-1303.
49. Walter M.F., Jacob R.F., Day C.A., Dahlborg R., Weng Y., Mason R.P. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004, 177:235-243.
50. Pereira-Leite C., Nunes C., Lima J.L., Reis S., Lucio M. Interaction of celecoxib with membranes: the role of membrane biophysics on its therapeutic and toxic effects. J Phys Chem B 2012, 116:13608-13617.
51. Nunes C., Brezesinski G., Pereira-Leite C., Lima J.L., Reis S., Lucio M. NSAIDs interactions with membranes: a biophysical approach. Langmuir 2011, 27:10847-10858.
52. Maier T.J., Schiffmann S., Wobst I., et al. Cellular membranes function as a storage compartment for celecoxib. J Mol Med (Berl) 2009, 87:981-993.
53. Petruzzelli M., Moschetta A., Renooij W., et al. Indomethacin enhances bile salt detergent activity: relevance for NSAIDs-induced gastrointestinal mucosal injury. Dig Dis Sci 2006, 51:766-774.
54. Hofmann A.F. Bile acids: the good, the bad, and the ugly. News Physiol Sci 1999, 14:24-29.
55. Petruzzelli M., Vacca M., Moschetta A., et al. Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. Clin Biochem 2007, 40:503-510.
56. Ligumsky M., Golanska E.M., Hansen D.G., Kauffman G.L. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat. Gastroenterology 1983, 84:756-761.
57. Abtahi F.S., Djahanguiri B. Decreased incidence of indomethacin-induced gastric ulceration in rats by bile duct diversion. Br J Surg 1975, 62:113-114.
58. Lugea A., Antolin M., Mourelle M., Guarner F., Malagelada J.R. Deranged hydrophobic barrier of the rat gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs. Gastroenterology 1997, 112:1931-1939.
59. Barrios J.M., Lichtenberger L.M. Role of biliary phosphatidylcholine in bile acid protection and NSAID injury of the ileal mucosa in rats. Gastroenterology 2000, 118:1179-1186.
60. Prakash P., Sayyed-Ahmad A., Zhou Y., et al. Aggregation behavior of ibuprofen, cholic acid and dodecylphosphocholine micelles. Biochim Biophys Acta 2012, 1818:3040-3047.